1. Home
  2. GEN vs DVA Comparison

GEN vs DVA Comparison

Compare GEN & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gen Digital Inc.

GEN

Gen Digital Inc.

HOLD

Current Price

$28.99

Market Cap

18.6B

Sector

Technology

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$184.23

Market Cap

14.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEN
DVA
Founded
1982
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Misc Health and Biotechnology Services
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.6B
14.9B
IPO Year
1995
2003

Fundamental Metrics

Financial Performance
Metric
GEN
DVA
Price
$28.99
$184.23
Analyst Decision
Buy
Hold
Analyst Count
8
4
Target Price
$32.88
$156.75
AVG Volume (30 Days)
5.5M
597.0K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
2.61%
N/A
EPS Growth
52.43
N/A
EPS
0.36
6.86
Revenue
$6,676,000,000.00
$13,643,069,000.00
Revenue This Year
$27.40
$3.85
Revenue Next Year
$5.41
$3.07
P/E Ratio
$83.92
$26.69
Revenue Growth
N/A
6.46
52 Week Low
$17.78
$101.00
52 Week High
$31.65
$247.49

Technical Indicators

Market Signals
Indicator
GEN
DVA
Relative Strength Index (RSI) 45.21 46.70
Support Level $25.26 $173.99
Resistance Level $29.87 $202.63
Average True Range (ATR) 0.77 5.37
MACD -0.20 2.04
Stochastic Oscillator 2.38 43.00

Price Performance

Historical Comparison
GEN
DVA

About GEN Gen Digital Inc.

Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.

About DVA DaVita Inc.

DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Share on Social Networks: